Ramesh Swaminathan, Executive Director and CFO of Lupin, says India’s weight-loss drug market could reach $1 billion, and expects Lupin to secure a strong share once semaglutide’s patent expires in March 2026.
Breakdown
- Lupin sees a global opportunity for semaglutide, targeting India, South Africa, Canada, Brazil, and China.
- India is viewed as a key market, with semaglutide's potential valued at nearly $1 billion due to high diabetes rates. 6s
- Lupin expects to capture a significant share of India's semaglutide market, leveraging its leadership in diabetes and cardiovascular drugs. 19s
- The company is monitoring U.S. policy changes that could impact pharmaceutical manufacturing costs and access, but remains optimistic about its U.S. prospects. 39s
- Lupin is expanding its manufacturing and R&D presence in both India and the U.S., including facilities in Somerset and Florida. 1m 41s